Company / Return on Equity (ROE)
Celldex Therapeutics, Inc. Return on Equity (ROE) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-49.1%
FY2025
5-year range
-49.1% / -21.1%
FY2023-FY2025
Trend
-132.3%
vs FY2024
Sector context
#137 of 147
Health Care
What the data says
Celldex Therapeutics, Inc. reports negative total equity of -49.1% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-49.1% in FY2025.
Declined from -33.0% to -49.1% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 147This company -49.1% Sector average -3.3%
▼
-1390.5% below sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 132.3% year-over-year.
- Currently 45.8pp below the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -49.1% | -132.3% |
| FY2024 | -21.1% | +35.9% |
| FY2023 | -33.0% | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026